Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results

Savara (NASDAQ:SVRA) announced its earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01), Zacks reports.

Savara Stock Performance

Shares of SVRA traded down $0.05 during trading hours on Thursday, hitting $4.21. The company’s stock had a trading volume of 25,331 shares, compared to its average volume of 1,239,882. The company has a market cap of $581.78 million, a price-to-earnings ratio of -11.51 and a beta of 1.00. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. The business has a 50 day simple moving average of $4.28 and a two-hundred day simple moving average of $4.61. Savara has a 52-week low of $3.12 and a 52-week high of $5.70.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. JMP Securities cut their price objective on Savara from $10.00 to $9.00 and set a “market outperform” rating on the stock in a research report on Tuesday. Guggenheim boosted their price target on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Savara in a report on Wednesday. Oppenheimer boosted their target price on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. Finally, Evercore ISI decreased their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, May 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara has an average rating of “Buy” and a consensus price target of $11.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.